MARKET

ARTV

ARTV

ARTIVA BIOTHERAPEUTICS INC
NASDAQ
9.70
+0.12
+1.25%
After Hours: 9.70 0 0.00% 16:28 06/30 EDT
OPEN
9.87
PREV CLOSE
9.58
HIGH
10.00
LOW
9.55
VOLUME
490.10K
TURNOVER
--
52 WEEK HIGH
14.53
52 WEEK LOW
1.480
MARKET CAP
471.31M
P/E (TTM)
-2.7329
1D
5D
1M
3M
1Y
5Y
1D
Major Stake Boost Signals Growing Confidence in Artiva Biotherapeutics
TipRanks · 1d ago
RA Capital Management reports $292,129 Artiva Biotherapeutics common share purchase
PUBT · 1d ago
Weekly Report: what happened at ARTV last week (0622-0626)?
Weekly Report · 1d ago
Artiva Biotherapeutics to join H.C. Wainwright Cell Therapy Virtual Conference fireside chat
PUBT · 06/23 20:05
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Barchart · 06/23 15:05
Weekly Report: what happened at ARTV last week (0615-0619)?
Weekly Report · 06/22 09:17
Major Insider Makes Bold New Bet on Artiva Biotherapeutics Stock
TipRanks · 06/17 02:07
RA Capital Management reports USD 4.56 million Artiva Biotherapeutics common stock acquisition
PUBT · 06/16 22:08
More
About ARTV
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.

Webull offers Artiva Biotherapeutics Inc stock information, including NASDAQ: ARTV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARTV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARTV stock methods without spending real money on the virtual paper trading platform.